Newlink Genetics Corporation (LUMO)

$3.93

+0.2

(+5.36%)▲

Market is closed - opens 7 PM, 16 Sep 2024

Performance

  • $3.61
    $3.93
    $3.93
    downward going graph

    8.14%

    Downside

    Day's Volatility :8.14%

    Upside

    0.0%

    downward going graph
  • $1.37
    $4.55
    $3.93
    downward going graph

    65.14%

    Downside

    52 Weeks Volatility :69.89%

    Upside

    13.63%

    downward going graph

Returns

PeriodNewlink Genetics CorporationSector (Health Care)Index (Russel 2000)
3 Months
49.8%
6.8%
0.0%
6 Months
25.59%
6.4%
0.0%
1 Year
14.42%
17.3%
0.0%
3 Years
-64.94%
17.7%
-21.1%

Highlights

Market Capitalization
28.9M
Book Value
$1.26
Earnings Per Share (EPS)
-4.42
Wall Street Target Price
21.75
Profit Margin
0.0%
Operating Margin TTM
-1603.07%
Return On Assets TTM
-60.5%
Return On Equity TTM
-132.56%
Revenue TTM
1.5M
Revenue Per Share TTM
0.18
Quarterly Revenue Growth YOY
-7.3999999999999995%
Gross Profit TTM
1.5M
EBITDA
-37.6M
Diluted Eps TTM
-4.42
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-3.57
EPS Estimate Next Year
-2.19
EPS Estimate Current Quarter
-1.24
EPS Estimate Next Quarter
-0.34

Analyst Recommendation

Buy
    90%Buy
    9%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Newlink Genetics Corporation(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
10
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 453.44%

Current $3.93
Target $21.75

Company Financials

FY18Y/Y Change
Revenue
1.2M
↑ 209.23%
Net Income
-53.6M
↓ 25.51%
Net Profit Margin
-4.4K%
↑ 14004.94%
FY19Y/Y Change
Revenue
936.0K
↓ 22.39%
Net Income
-43.0M
↓ 19.79%
Net Profit Margin
-4.6K%
↓ 148.81%
FY20Y/Y Change
Revenue
168.0K
↓ 82.05%
Net Income
-5.7M
↓ 86.83%
Net Profit Margin
-3.4K%
↑ 1222.01%
FY21Y/Y Change
Revenue
230.0K
↑ 36.9%
Net Income
-30.4M
↑ 437.35%
Net Profit Margin
-13.2K%
↓ 9859.6%
FY22Y/Y Change
Revenue
1.5M
↑ 562.17%
Net Income
-31.1M
↑ 2.08%
Net Profit Margin
-2.0K%
↑ 11190.9%
FY23Y/Y Change
Revenue
2.1M
↑ 34.67%
Net Income
-34.0M
↑ 9.57%
Net Profit Margin
-1.7K%
↑ 380.14%
Q1 FY23Q/Q Change
Revenue
691.0K
↑ 34.96%
Net Income
-6.7M
↓ 13.23%
Net Profit Margin
-963.39%
↑ 535.05%
Q2 FY23Q/Q Change
Revenue
527.0K
↓ 23.73%
Net Income
-8.9M
↑ 34.16%
Net Profit Margin
-1.7K%
↓ 731.3%
Q3 FY23Q/Q Change
Revenue
7.0K
↓ 98.67%
Net Income
-8.3M
↓ 7.07%
Net Profit Margin
-118.6K%
↓ 116876.74%
Q4 FY23Q/Q Change
Revenue
826.0K
↑ 11700.0%
Net Income
-9.5M
↑ 13.94%
Net Profit Margin
-1.1K%
↑ 117426.51%
Q1 FY24Q/Q Change
Revenue
165.0K
↓ 80.02%
Net Income
-10.4M
↑ 10.4%
Net Profit Margin
-6.3K%
↓ 5182.96%
Q2 FY24Q/Q Change
Revenue
488.0K
↑ 195.76%
Net Income
-7.6M
↓ 27.68%
Net Profit Margin
-1.5K%
↑ 4780.54%
FY18Y/Y Change
Total Assets
130.9M
↓ 27.54%
Total Liabilities
15.8M
↓ 45.79%
FY19Y/Y Change
Total Assets
96.8M
↓ 26.08%
Total Liabilities
17.9M
↑ 13.38%
FY20Y/Y Change
Total Assets
129.0M
↑ 33.32%
Total Liabilities
12.5M
↓ 30.42%
FY21Y/Y Change
Total Assets
100.3M
↓ 22.26%
Total Liabilities
11.3M
↓ 9.04%
FY22Y/Y Change
Total Assets
72.3M
↓ 27.93%
Total Liabilities
12.7M
↑ 12.11%
FY23Y/Y Change
Total Assets
40.6M
↓ 43.79%
Total Liabilities
13.3M
↑ 4.92%
Q1 FY23Q/Q Change
Total Assets
63.7M
↓ 11.85%
Total Liabilities
11.2M
↓ 11.82%
Q2 FY23Q/Q Change
Total Assets
56.4M
↓ 11.54%
Total Liabilities
12.7M
↑ 13.44%
Q3 FY23Q/Q Change
Total Assets
47.8M
↓ 15.29%
Total Liabilities
12.3M
↓ 3.56%
Q4 FY23Q/Q Change
Total Assets
40.6M
↓ 14.9%
Total Liabilities
13.3M
↑ 8.76%
Q1 FY24Q/Q Change
Total Assets
28.1M
↓ 30.91%
Total Liabilities
10.6M
↓ 20.21%
Q2 FY24Q/Q Change
Total Assets
21.4M
↓ 23.94%
Total Liabilities
11.1M
↑ 4.15%
FY18Y/Y Change
Operating Cash Flow
-37.9M
↓ 21.42%
Investing Cash Flow
117.0K
↓ 44.55%
Financing Cash Flow
-148.0K
↓ 100.2%
FY19Y/Y Change
Operating Cash Flow
-30.2M
↓ 20.38%
Investing Cash Flow
77.0K
↓ 34.19%
Financing Cash Flow
-59.0K
↓ 60.14%
FY20Y/Y Change
Operating Cash Flow
-23.0M
↓ 23.87%
Investing Cash Flow
116.6M
↑ 151392.21%
Financing Cash Flow
75.0K
↓ 227.12%
FY21Y/Y Change
Operating Cash Flow
-29.6M
↑ 28.92%
Investing Cash Flow
26.0M
↓ 77.74%
Financing Cash Flow
-192.0K
↓ 356.0%
FY22Y/Y Change
Operating Cash Flow
-26.6M
↓ 10.2%
Investing Cash Flow
-11.4M
↓ 143.74%
Financing Cash Flow
-821.0K
↑ 327.6%
Q1 FY23Q/Q Change
Operating Cash Flow
-9.2M
↑ 57.86%
Investing Cash Flow
1.1M
↓ 109.54%
Financing Cash Flow
-309.0K
↓ 34.95%
Q2 FY23Q/Q Change
Operating Cash Flow
-6.7M
↓ 27.31%
Investing Cash Flow
1.1M
↑ 0.0%
Financing Cash Flow
-574.0K
↑ 85.76%

Technicals Summary

Sell

Neutral

Buy

Newlink Genetics Corporation is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Newlink Genetics Corporation
Newlink Genetics Corporation
70.32%
25.59%
14.42%
-64.94%
99.47%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
0.53%
20.61%
40.93%
82.08%
313.49%
Novo Nordisk A/s
Novo Nordisk A/s
2.31%
2.37%
41.89%
174.22%
452.16%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
-2.2%
76.34%
35.57%
40.87%
212.74%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
2.37%
15.84%
38.0%
150.97%
173.61%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Newlink Genetics Corporation
Newlink Genetics Corporation
NA
NA
NA
-3.57
-1.33
-0.6
NA
1.26
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
30.21
30.21
1.55
45.05
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
45.38
45.38
2.06
3.41
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.55
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.58
0.32
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Newlink Genetics Corporation
Newlink Genetics Corporation
Buy
$28.9M
99.47%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$125.3B
313.49%
30.21
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$576.2B
452.16%
45.38
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$33.6B
212.74%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$123.5B
173.61%
32.84
-4.74%

Insights on Newlink Genetics Corporation

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 165.0K → 488.0K (in $), with an average increase of 66.2% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -10.44M → -7.55M (in $), with an average increase of 38.3% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 41.9% return, outperforming this stock by 27.5%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 174.2% return, outperforming this stock by 239.1%

Institutional Holdings

  • Wells Fargo & Co

    5.11%

  • Goldman Sachs Group Inc

    5.01%

  • Vanguard Group Inc

    3.00%

  • Renaissance Technologies Corp

    2.66%

  • Acuitas Investments, LLC

    1.74%

  • Jefferies Financial Group Inc

    1.49%

Company Information

lumos pharma is an clinical stage biotechnology company focused on developing therapeutics for rare diseases

Organization
Newlink Genetics Corporation
Employees
33
CEO
Mr. Richard J. Hawkins
Industry
Health Technology

Discover More

FAQs